Investment Column: Oxford Asym

Tuesday 27 July 1999 23:02 BST

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

OXFORD ASYMMETRY'S shares have fallen off recently from 574p to 371p amid concerns that it may not meet profits forecasts this year. The company prepares compounds for biotechnology and pharmaceuticals companies. It estimates it has less than 1 per cent of the market in each of its activities. That market is set to grow as pharmaceutical companies outsource compound preparation.

Interim results, however, showed profits falling off slightly because corporate activity among pharmaceuticals companies has put a squeeze on OA's market. That should not deter investors. OA is mulling a US tie-up to capitalise on its strong reputation. Analysts expect profits of pounds 3.7m and earnings of 8.3p per share this year. Buy.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Stay up to date with notifications from The Independent

Thank you for registering

Investment Column: Oxford Asym

Join our commenting forum

Thank you for registering